vidual protection afforded to vaccineesin other words there was evidence that some herd immunity had developed. It is interesting that Type 2 virus virtually disappeared (Bodian 1961) , but that Types 1 and 3 virus persisted, though mainly in poorly vaccinated areas. Could this have been related in any way to the differing potency of the three antigenic components of Salk vaccine? In this connexion it is worth noting that in Sweden, where potency levels were high for all three virus types, 'wild' polioviruses did virtually disappear.
The mechanism whereby Salk vaccine can influence the spread of 'wild' polioviruses in a community is of interest. In the infected person poliovirus multiplies in the throat and in the small intestine, but the relative importance of these two sites in the transmission of the infection is an unresolved problem. Probably both are important. It is generally believed that, in persons who have received Salk vaccine, virus growth in the throat is inhibited, and certainly this is what we have found in Belfast (Dick et al. 1961) , but that multiplication in the small intestine is not. In a trial carried out in 1960 we compared the faecal virus excretion by a group of children who had received only two doses of ordinary Salk vaccine with the excretion by an unvaccinated control group after both had received a dose of attenuated Type 2 poliovirus. The mean frecal virus excretion of the two groups for the twenty-day period after feeding virus was virtually identical.
In 1963 we carried out a similar trial, but on this occasion the test group of children had received a full course of Salk vaccine and therefore had a higher mean antibody titre than the children in this first group -1: 7,000 as opposed to 1: 500.
The mean level of fecal virus excretion by the vaccinated group was only one-twentieth of that of the control group. The inhibition of throat virus multiplication together with this marked reduction in fecal virus excretion may well explain the herd immunity which has followed the use of Salk vaccine. The degree of individual protection obtained and the degree of herd immunity which follows wide-scale use both appeared to depend on vaccine potency.
Conclusion
Both oral vaccine and the new Salk vaccines appear to be efficient and have approximately equal capacities for protecting the individual and the herd. It would seem wise, until we know more about them, not to pin our faith too firmly upon one or the other. We may yet have something to learn about their safety. There are certain complications of immunizing procedures which can be recognized in the individual patient. For example, the child who develops generalized vaccinia after vaccination against smallpox is suffering from a form of illness which does not occur naturally, the lesions resemble those produced by the immunizing agent and, if confirmation is needed, vaccinia virus can be isolated from the lesions. Most local reactions to immunization can also be recognized in the individual, whether they occur soon after, like the sore arm of TAB vaccination, or are delayed, like the cysts which may develop after the injection of an oil-adjuvant vaccine. There are also certain well-established patterns of general reaction, some immediate or nearly so, such as anaphylactoid reactions, some delayed, like serum sickness.
But, when the complication or alleged complication of an immunizing procedure takes the form of an illness which may also occur naturally or spontaneously, it is usually impossible in the individual case to decide whether the illness is causally related to the immunizing procedure or not. In the early days of Salk vaccination the chief concern which was felt about the safety of the vaccine was that the polioviruses used in its preparation might have been imperfectly inactivated and so capable of giving rise to poliomyelitis in vaccinated persons and, although the most stringent laboratory tests were made on every batch of vaccine released, the ultimate assurance of safety lay in its effects when inoculated into man. In any individual instance of a person who was living in a community where natural poliovirus infection was occurring and who developed the disease soon after an injection of Salk vaccine it was impossible to say whether this was a coincidence or whether the vaccine was responsible for the illness. It was necessary, therefore, to proceed by accumulating instances of association of vaccination with subsequent poliomyelitis and comparing these with what could be expected to have occurred as natural events. In order to detect inoculation poliomyelitis the most significant kinds of association were: (1) An unduly high incidence of poliomyelitis in vaccinated persons. (2) An aggregation of dates of onset of illness within a month of vaccination, particularly from four to fourteen days. (3) An undue proportion of persons paralysed in the inoculated limb. (4) An undue proportion of cases associated with a single batch, or a small number of batches, of vaccine.
These considerations formed the basis of the surveillance scheme which was put into operation when Salk vaccination was first introduced into England and Wales in 1956.
All Medical Officers of Health were asked to report to the Ministry, by telephone or telegram, any case of poliomyelitis occurring in a vaccinated person. These reports were followed up by medical officers of the Ministry with the Medical Officers of Health concerned and, if necessary, with the clinicians in charge of the patients in order to get as full information as possible. We had a standard form for the record of each case giving identifying particulars, age and sex, type of illness (paralytic or nonparalytic), severity, site of paralysis, date of onset of illness and of paralysis, and details of poliomyelitis vaccination history.
A running analysis was kept, with the primary object of detecting any repetition of the Cutter incident (Nathanson & Langmuir 1963) at the earliest possible stage. Quite a number of the cases initially reported turned out not to be poliomyelitis at allfebrile nonparalytic illnesses due to other causes, muscular weakness due to trauma and the like. But after the clinicians had revised their provisional diagnoses there remained a substantial number of cases of undoubted poliomyelitis in vaccinated persons, though with no indication of any causal relationship.
When a considerable volume of information had accumulated it was thought desirable to review the situation and to see what conclusions could be drawn about the safety and efficacy of the vaccine. Geffen & Spicer (1960) undertook a thorough review of every case of poliomyelitis notified in England and Wales in 1958. They reported on 242 cases of poliomyelitis in vaccinated persons, about 12% of the corrected notifications for the year, of which 54 paralytic cases and 26 nonparalytic cases occurred within twentyeight days of an injection of Salk vaccine. Comparing the estimated incidence of the disease in vaccinated and unvaccinated groups and taking into account the time intervals from vaccination to onset of illness, the site of paralysis and other factors, they concluded that the figures did not suggest that the vaccine caused either inoculation poliomyelitis or provocation paralysis and did provide confirmatory evidence of the efficacy of two or more doses of vaccine as a protection against poliomyelitis. Geffen (1960) repeated this exercise on notifications of poliomyelitis in 1959. In this second series, 230 cases (22% of the total notifications) were in vaccinated persons and of these 34 paralytic cases and 12 nonparalytic cases occurred within twenty-eight days of an injection of Salk vaccine. These figures again were shown to be consistent with both safety and efficacy, the estimated incidence of poliomyelitis in the unvaccinated being of the order of 6 to 8 times that in the previously vaccinated. If the only information available had been of the vaccine-associated cases, it would have been impossible from a consideration of these alone to draw any conclusion whatever about the safety or efficacy of the vaccine. It was only because reasonably complete knowledge was also available of the incidence of poliomyelitis in all parts of the country, poliomyelitis being a statutorily notifiable disease, that any statistical appreciation could be made of the significance of the association.
While we were systematically collecting data on poliomyelitis in vaccinated persons we were incidentally receiving other information about possible adverse reactions or complications. Some of these appeared to be causally related: for example, the rare allergic or anaphylactoid reactions in persons known to be or subsequently shown to be hypersensitive to penicillin, of which there were traces in most of the earlier vaccines. Some appeared to be coincidental.
The general consensus of opinion was that this was a singularly bland vaccine associated with few local reactions and with very rare general reactions. But there were occasional reports of neurological disorders which gave rise to a certain amount of disquiet. Some of these took the form of convulsions in infancy or early chidhood, a story reminiscent of the complications of whooping-cough vaccination. As early as 1956 a child of 18 months had convulsions about fifteen to eighteen hours after a first injection of Salk vaccine and developed hemiparesis three days later. In 1957 a child aged 3i, who had had epilepsy since the age of 2, developed convulsions twelve hours after a first injection of Salk vaccine. There have been a few cases of a similar nature reported in subsequent years. With the greater extension of poliomyelitis vaccination in 1958 other forms of neurological disorder began to occur, with sensory or motor changes or ataxia as prominent features, though it was some time before many of them came to light. By July 1961 it was possible to present to the Joint Committee on Poliomyelitis Vaccine a summary of 16 cases, described variously as encephalitis, meningo-encephalitis, encephalomyelitis, cerebellar ataxia and disseminated sclerosis, mostly in adolescents or young adults, with onset of symptoms ranging from one to forty days after a first, second or third injection of Salk vaccine.
The Joint Committee considered the summary and reached the following conclusion: 'Cases of neurological lesions following poliomyelitis vaccination have been reported but in most of them a causal relationship is improbable. Even where there is such a possibility the incidence in relation to the total number of persons vaccinated is so extremely low that the risk can be discounted.' Table 1 shows the progress of Salk vaccination in England and Wales during the period under review. By the end of 1961 more than 16,000,000 persons had been given two doses of vaccine and, of these, more than 12,000,000 had been given a third dose. Table 2 shows the number of neurological illnesses, other than poliomyelitis, reported after Salk vaccination in England and Wales from 1956 to 1963. These have been classified according to the predominant clinical feature in the acute stage of illness. Convulsive disorders occurred almost exclusively among children (6 of the 7 cases reported), the only exception being an adult, aged 28 years, who had meningococcal meningitis in infancy, suffered from repeated 'fainting attacks' subsequently and passed into status epilepticus seven days after a first injection of Salk vaccine. The 6 neurological disorders, classified as febrile, formed a heterogeneous group with no discernible clinical pattern in common. The most promising group for further study appeared to be those classified as ataxic. In 5 instances a diagnosisof disseminated sclerosis had been made, but, in 2 of these, symptoms suggestive of the disease were present before vaccination was begun, parmesthesia for nine years in one case and an unsteady gait for eighteen months in the other. I have excluded these 2 cases from further consideration but I have included one of the cases, classified as febrile, in which ataxia subsequently developed. There were 5 examples, including 2 cases of disseminated sclerosis, of ataxia developing within three weeks after a first injection, one case of disseminated sclerosis of onset six weeks after a second injection and 3 ataxic illnesses which developed within four weeks after a third injection. The recommended interval between the first and second injections is 3 -6 weeks and between the second and third injections 7 -12 months.
The clustering of cases might suggest a causal relationship between an injection of Salk vaccine and the development of an ataxic illness. The data, however, do not include the number of ataxic illnesses which could be expected to have occurred as natural events in a population of more than 12,000,000 people to whom Salk vaccine was given during the period under review. I know of no source of information which could provide an estimate of this number. But there is some information about the incidence of disseminated sclerosis, which has been estimated in England and Wales at about 2 new cases per 100,000 population per year. On the most conservative estimate of the number of Salk-vaccinated persons aged 15-40 years, at least 3,000,000 were given two injections during the years 1958-61, and, applying the estimated incidence of disseminated sclerosis, at least 60 cases of this disease could be expected to have occurred among them within one year of their first injection. The data show only 3 such cases and, before any judgment can be reached as to the possibility of a causal relationship, the distribution of times of onset of the remaining 57 cases must be known. If these also tended to cluster soon after an injection, it would lend support to the view that a causal relationship might exist, but if, as seems more likely, they were distributed more or less evenly all that we have succeeded in demonstrating is that the onset of disease in some cases, by chance, happened to coincide with the period immediately following an injection of Salk vaccine.
